IonQ, Inc. — Q1 2024 Form 10-Q
Business context and period. IonQ develops trapped-ion quantum computing systems and sells specialized hardware, quantum-computing-as-a-service (QCaaS), and related consulting and support. This unaudited quarterly report covers the three months ended March 31, 2024, with comparison to Q1 2023. The company remains in an early commercial and development stage and operates as one reportable segment.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | $7.6 million | $4.3 million |
| Operating costs and expenses | $60.5 million | $32.3 million |
| Loss from operations | $(52.9) million | $(28.0) million |
| Net loss | $(39.6) million | $(27.3) million |
| Basic and diluted loss per share | $(0.19) | $(0.14) |
| Net cash used in operating activities | $(20.5) million | $(13.8) million |
| Cash, cash equivalents and available-for-sale investments | $434.4 million | $455.9 million at December 31, 2023 |
- Revenue increased 77% year over year, supported by progress on specialized-hardware arrangements and new service contracts. Hardware revenue was $3.6 million; platform, consulting and support revenue was $4.0 million.
- Cost of revenue, excluding depreciation and amortization, was $3.4 million, implying a 55% gross margin on that basis. This is not a fully burdened margin measure because depreciation and amortization is presented separately.
- Operating expenses rose substantially: research and development to $32.4 million (+99%), sales and marketing to $6.7 million (+151%), and general and administrative to $14.0 million (+33%). Stock-based compensation expense was $22.1 million, versus $10.3 million.
- Interest income was $4.8 million. A non-cash $8.6 million gain from remeasurement of warrant liabilities partly offset operating losses; Q1 2023 had a $3.6 million warrant-liability loss.
- Cash and cash equivalents were $60.1 million; short- and long-term investments were $374.4 million. A further $2.4 million of restricted cash is excluded from management’s $434.4 million liquidity figure. Investing cash flow was positive $43.5 million largely because investment maturities exceeded purchases, not from operating cash generation.
- Total assets were $543.9 million, total liabilities $64.1 million, and stockholders’ equity $479.8 million at March 31, 2024. No conventional borrowings are reported in the presented balance sheet. Operating lease obligations were reported as $23.9 million in total, with $2.8 million payable within 12 months; the balance sheet’s present value of lease liabilities was $15.6 million.
- Accumulated deficit was $391.7 million. Common shares outstanding at quarter-end were 210.8 million, up from 206.6 million at year-end 2023.
Material changes and operating developments
- Revenue growth was outpaced by expense growth, widening the operating loss to $52.9 million from $28.0 million. Management attributed higher costs chiefly to increased hiring and compensation, equity awards, R&D materials and equipment, and marketing activity.
- Operating cash use increased by $6.7 million year over year, reflecting higher R&D, compensation and public-company costs.
- Two customers represented 69% of Q1 revenue, compared with three customers representing 73% in Q1 2023.
- Remaining performance obligations were approximately $61.8 million, including funded and unfunded firm orders; the company expects about 40% to be recognized within 12 months. Unexercised options are excluded.
- Management highlighted early results from a DESY collaboration on airplane gate-assignment optimization, a new Oak Ridge National Laboratory collaboration, a South Carolina quantum partnership, construction of the first IonQ Forte Enterprise system for customer delivery, and preparation for a system at a Basel data center.
Outlook, risks and contingencies
- IonQ expects cash, cash equivalents and investments at March 31, 2024 to fund working capital and capital expenditures for at least the next 12 months. It also expects significant losses and higher operating expenses for the foreseeable future. The filing provides no quantified full-year revenue or earnings guidance in the supplied text.
- Longer-term funding may depend on operating cash flows and available funds, with potential additional equity, debt, or collaboration financing. Additional financing may be unavailable or dilutive; the company says development efforts could be delayed, reduced or terminated if funding is insufficient.
- Key business risks include the uncertain timeline and technical feasibility of scaling quantum computers, achieving higher fidelity and broad quantum advantage, manufacturing and supply constraints, dependence on a limited source of isotopically enriched materials, intense competition, and reliance on cloud-platform partners.
- Revenue concentration, long sales cycles, government-contract funding and termination risks, cybersecurity and data-privacy exposure, international and export-control requirements, inflation, interest rates, and access to capital could affect results and commercialization.
- A securities class action was dismissed with prejudice in September 2023; plaintiffs filed a post-judgment motion in October 2023 seeking to amend their complaint. The company says it cannot reasonably estimate any possible loss or range of loss.
- Management concluded disclosure controls and procedures were effective at a reasonable-assurance level as of March 31, 2024; no material change in internal control over financial reporting was reported during the quarter.
Investor verification priorities
- Confirm the composition and accessibility of the $434.4 million liquidity figure, investment maturities, and actual cash-burn trajectory.
- Track conversion and timing of the $61.8 million remaining performance obligations, distinguishing funded from unfunded orders, and monitor dependence on two major customers.
- Assess whether revenue growth can outpace operating-cost growth and whether reported margin comparisons account for separately presented depreciation and amortization.
- Monitor stock-based compensation, share-count growth and potential dilution from outstanding equity awards and warrants.
- Verify progress, delivery timing and commercial economics for customer systems and planned deployments, alongside technical milestones and manufacturing capacity.
- Follow developments in the post-judgment litigation motion and any other material legal, regulatory, supply-chain or financing contingencies.